Presents TriCell, ReWave, and Brifill at major Middle Eastern medical exhibition
REV-MED Booth at Arab Health 2025 / Image courtesy of REV-MED
[Global Epic | Reporter Seongsoo Hwang]
REV-MED participated in Arab Health 2025, the largest medical device exhibition in the Middle East, held from January 27 to 30 in Dubai, UAE, showcasing its autologous cell separation and concentration technology.
Based on its proprietary regenerative medicine technology, REV-MED is expanding its competitive presence in both Middle Eastern and European markets, and introduced its certified technologies at the event. The company has previously obtained regulatory certifications from Japan (PMDA) and China (NMPA).
In addition to the TriCell product line, REV-MED unveiled the Rewave—a skin regeneration and collagen-boosting device utilizing ultra-high-frequency (UHF) microwave technology—and Brifill, its HA filler product. These offerings aim to strengthen the company’s entry into the Middle Eastern aesthetic medicine sector.
A REV-MED representative commented,
"With Korea’s leading position in autologous biologics technology, we are aiming to lead not only the Middle East but the global market."
"We will expand R&D focused on treating intractable diseases and continue fostering academic collaborations worldwide."
Following the exhibition, REV-MED announced plans to expand partnerships in Saudi Arabia, Kuwait, and other countries, and has set 2025 revenue growth targets for the Middle Eastern market.
Reporter Seongsoo Hwang | hss@globalepic.co.kr
Source: Global Epic
Presents TriCell, ReWave, and Brifill at major Middle Eastern medical exhibition
REV-MED Booth at Arab Health 2025 / Image courtesy of REV-MED
[Global Epic | Reporter Seongsoo Hwang]
REV-MED participated in Arab Health 2025, the largest medical device exhibition in the Middle East, held from January 27 to 30 in Dubai, UAE, showcasing its autologous cell separation and concentration technology.
Based on its proprietary regenerative medicine technology, REV-MED is expanding its competitive presence in both Middle Eastern and European markets, and introduced its certified technologies at the event. The company has previously obtained regulatory certifications from Japan (PMDA) and China (NMPA).
In addition to the TriCell product line, REV-MED unveiled the Rewave—a skin regeneration and collagen-boosting device utilizing ultra-high-frequency (UHF) microwave technology—and Brifill, its HA filler product. These offerings aim to strengthen the company’s entry into the Middle Eastern aesthetic medicine sector.
A REV-MED representative commented,
"With Korea’s leading position in autologous biologics technology, we are aiming to lead not only the Middle East but the global market."
"We will expand R&D focused on treating intractable diseases and continue fostering academic collaborations worldwide."
Following the exhibition, REV-MED announced plans to expand partnerships in Saudi Arabia, Kuwait, and other countries, and has set 2025 revenue growth targets for the Middle Eastern market.
Reporter Seongsoo Hwang | hss@globalepic.co.kr
Source: Global Epic